Organ on a Chip Market Size & Growth Forecast 2027–2036, By Segments (Products & Service, Application, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Organ on a Chip Market size was more than USD 234.8 million in 2026 and is set to grow at a 25.08% CAGR between 2027 and 2036, exceeding USD 2.2 billion by 2036. The industry revenue for 2027 is calculated at USD 284.39 million.
Get more details on this report
Request Free Sample ReportOrgan on a Chip Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 54.60% share driven by advanced biomedical research base, strong pharma presence, and early adoption of organ-on-chip systems in drug discovery workflows.
- Europe grows at 37.51% CAGR due to increasing shift toward animal testing alternatives and rising use of microphysiological systems in drug screening and translational research.
Segment Momentum
- Services captured 54.79% of the market in 2026 because many users rely on specialized expertise for study design, model customization, assay execution, and data interpretation.
- Products are growing fastest as organizations bring organ-on-chip capabilities in-house to gain greater control over testing timelines, protocol flexibility, and research standardization.
Market Expansion Drivers
- Increasing demand for animal testing alternatives accelerating organ-on-chip adoption in drug discovery.
- Advancements in microfluidics enabling physiologically relevant disease modeling and therapeutic evaluation.
- Expanding precision medicine research driving development of personalized organ-chip diagnostic platforms.
Leading Market Participants
- Key companies in the organ on a chip market include Emulate, Inc. (United States), MIMETAS B.V. (Netherlands), CN Bio Innovations Ltd (United Kingdom), Valo Health, Inc. (United States), BICO Group AB (Sweden), AxoSim, Inc. (United States), Nortis, Inc. (United States), AlveoliX AG (Switzerland), SynVivo, Inc. (United States), The Charles Stark Draper Laboratory, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 234.8 million
- 2027 Estimated Market Size: USD 284.39 million.
- Projected Market Size: USD 2.2 billion by 2036
- Growth Forecast: 25.08% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Europe
- Core Revenue Segment: Services (Products & Service) | Drug Discovery (Application) | Pharmaceutical & Biotechnology Companies (End Use)
- Emerging Opportunity Segment: Products (Products & Service) | Toxicology Research (Application) | Academic & Research Institutes (End Use)
Market Growth Drivers and Industry Trends
Increasing demand for animal testing alternatives accelerating organ-on-chip adoption in drug discovery
Increasing demand for alternatives to animal testing will drive the organ on a chip market growth as pharmaceutical and research organizations seek experimental models that can provide more human-relevant biological responses. Organ-on-chip systems recreate selected features of human tissues and organ functions within controlled laboratory environments, supporting the evaluation of drug effects and toxicity. Their ability to model biological interactions in a more targeted manner provides researchers with an additional platform for assessing therapeutic candidates during drug development.
Advancements in microfluidics enabling physiologically relevant disease modeling and therapeutic evaluation
Advancements in microfluidic technologies will propel the organ on a chip market growth by enabling tighter control over fluid flow, cellular environments, and interactions within miniature biological systems. Improved microfluidic designs can replicate important physiological conditions and create controlled environments for studying disease mechanisms and treatment responses. These capabilities allow researchers to evaluate cellular and tissue behavior under dynamic conditions that are difficult to reproduce using conventional static laboratory models.
Expanding precision medicine research driving development of personalized organ-chip diagnostic platforms
Expanding precision medicine research will boost the organ on a chip market demand by encouraging development of models that reflect individual patient characteristics and biological responses. Personalized organ-chip platforms can incorporate patient-derived cells or other individualized biological information to investigate how specific tissues may respond to therapies. Such approaches support more tailored therapeutic evaluation and provide researchers with tools for studying disease behavior and treatment effectiveness in patient-relevant biological models.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing demand for animal testing alternatives accelerating organ-on-chip adoption in drug discovery | 2.20% | High | North America, Europe | High | Near Term |
| Advancements in microfluidics enabling physiologically relevant disease modeling and therapeutic evaluation | 2.00% | High | North America, Asia Pacific | High | Mid Term |
| Expanding precision medicine research driving development of personalized organ-chip diagnostic platforms | 1.70% | Moderate | Asia Pacific, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the organ on a chip market with a 54.60% share in 2026, supported by advanced biomedical research infrastructure, strong adoption of innovative laboratory technologies, and growing demand for alternatives to conventional experimental models. The region's established research environment encourages the use of organ-on-chip platforms for drug development, disease modeling, and toxicity assessment. Increasing emphasis on improving research efficiency and developing more physiologically relevant testing approaches continues to reinforce regional adoption.
Europe (Fastest-Growing Region)
Europe is the fastest-growing region, driven by strong interest in advanced biomedical research, increasing focus on innovative drug-development methods, and growing demand for technologies that can improve preclinical testing. The region's emphasis on scientific innovation and more efficient research methodologies is creating favorable conditions for organ-on-chip applications. Expanding collaboration across research and healthcare ecosystems is also supporting greater integration of these platforms into pharmaceutical and life-science workflows.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Engineering-Driven ValidationGermany emphasizes organ on a chip development through precision engineering and multidisciplinary biomedical research. Organizations in Germany continue refining microphysiological systems that improve pharmaceutical testing reliability and support alternative research methodologies.
France 🇫🇷
Translational Testing SolutionsFrance prioritizes organ on a chip applications that bridge laboratory research with pharmaceutical development and toxicology assessment. Research organizations in France continue strengthening collaborative innovation to improve predictive testing models for biomedical applications.
Italy 🇮🇹
Preclinical Research EnhancementItaly is expanding organ on a chip adoption across biomedical research institutions seeking more representative preclinical testing platforms. Organizations in Italy increasingly integrate these systems into collaborative research programs that improve experimental efficiency and therapeutic evaluation.
Japan 🇯🇵
Pharmaceutical Research IntegrationJapan integrates organ on a chip platforms into pharmaceutical research to improve disease modeling and therapeutic evaluation. Research institutions in Japan increasingly adopt advanced microfluidic technologies that enhance laboratory efficiency and biologically relevant testing outcomes.
South Korea 🇰🇷
Microfluidics Innovation FocusSouth Korea advances organ on a chip technologies through investments in microfluidics, biomedical engineering, and biotechnology collaboration. Companies in South Korea continue developing versatile testing platforms that support drug development and precision medicine research.
United States 🇺🇸
Advanced Drug ScreeningThe U.S. organ on a chip market focuses on improving drug discovery through predictive human tissue models that enhance preclinical evaluation. Pharmaceutical companies and research organizations in the U.S. continue adopting these platforms to optimize testing efficiency and reduce experimental limitations.
Segment Leadership and Growth Trends
Organ on a Chip Market Share (%), by Products & Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProducts & Service Segment Analysis: Services (Largest Segment) vs Products (Fastest-Growing Segment)
Services accounted for the largest share of the organ on a chip market at 54.79% in 2026, reflecting the specialized expertise required to design, develop, validate, and operate organ-on-chip platforms for research applications. Organizations often require technical support for experimental design, model customization, data interpretation, and integration with existing research workflows. The complexity of developing physiologically relevant models and the need for specialized technical capabilities continue to support demand for service-based offerings.
Products are expected to register the fastest growth as researchers increasingly adopt standardized organ-on-chip platforms and ready-to-use systems for biological and pharmaceutical investigations. Product development is improving accessibility to sophisticated tissue models while supporting more consistent experimentation across research environments. Increasing interest in alternatives to conventional laboratory models, along with the need for scalable and reproducible testing platforms, is creating stronger demand for commercially available organ-on-chip products.
Application Segment Analysis: Drug Discovery (Largest Segment) vs Toxicology Research (Fastest-Growing Segment)
Drug discovery led the organ on a chip market with a 60.9% share in 2026, driven by the growing use of physiologically relevant human tissue models to investigate drug responses and improve preclinical evaluation. Organ-on-chip systems can replicate important aspects of human organ function, enabling researchers to examine drug interactions and biological responses under controlled conditions. Increasing demand for more predictive research models and improved efficiency in pharmaceutical development is strengthening the role of organ-on-chip technologies in drug discovery.
Toxicology research is projected to be the fastest-growing application as researchers increasingly seek advanced models for evaluating drug safety and potential adverse biological effects. Organ-on-chip platforms can provide more physiologically representative environments for studying tissue responses and toxicity than conventional simplified models. Rising emphasis on improving preclinical safety assessment, reducing uncertainty in development programs, and obtaining more human-relevant biological insights is supporting broader adoption in toxicology research.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Products & Service | Products, Services | Services | Products |
| Application | Drug Discovery, Toxicology Research, Others | Drug Discovery | Toxicology Research |
| End Use | Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others | Pharmaceutical & Biotechnology Companies | Academic & Research Institutes |
Competitive Landscape and Market Positioning
Key companies in the organ on a chip market:
1. Emulate Inc. (United States)
2. MIMETAS B.V. (Netherlands)
3. CN Bio Innovations Ltd (United Kingdom)
4. Valo Health Inc. (United States)
5. BICO Group AB (Sweden)
6. AxoSim Inc. (United States)
7. Nortis Inc. (United States)
8. AlveoliX AG (Switzerland)
9. SynVivo Inc. (United States)
10. The Charles Stark Draper Laboratory Inc. (United States)
The organ on a chip market is evolving rapidly with growing emphasis on the development of physiologically relevant models that improve drug testing accuracy and disease simulation capabilities. Research partnerships and interdisciplinary collaborations are enabling faster advancements in microengineered systems and tissue modeling technologies. Within the organ on a chip market, companies are also concentrating on expanding application areas across toxicology studies, pharmaceutical development, and precision medicine research.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Emulate Inc. (United States) | |||||||
| MIMETAS B.V. (Netherlands) | |||||||
| CN Bio Innovations Ltd (United Kingdom) | |||||||
| Valo Health Inc. (United States) | |||||||
| BICO Group AB (Sweden) | |||||||
| AxoSim Inc. (United States) | |||||||
| Nortis Inc. (United States) | |||||||
| AlveoliX AG (Switzerland) | |||||||
| SynVivo Inc. (United States) | |||||||
| The Charles Stark Draper Laboratory Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Axoft | May-26 | Axoft secured USD 55 million in Series A funding to advance its neurotechnology and chip-based platforms. The capital injection supports the expansion of its R&D capabilities and the engineering of advanced biological interface technologies, accelerating its positioning in next-generation bio-integrated and organ-on-chip systems. |
| Roche | May-26 | Roche announced an industrial collaboration with Nvidia to build an AI-enabled facility and integrate advanced computational chip technologies into drug development workflows. The initiative represents an infrastructure investment in microphysiological and digital simulation platforms to reduce reliance on conventional animal testing models. |
| Woojung Bio | Apr-26 | Woojung Bio entered a multiyear collaboration with Xellar Biosystems to develop artificial intelligence and computer vision–enabled organ-on-a-chip platforms. The partnership aims to integrate hybrid preclinical microphysiological screening systems to improve drug discovery accuracy and offer viable alternatives to traditional animal testing. |
| Qureator | Oct-25 | Qureator achieved a regulatory milestone under the FDA Modernization Act 2.0 by utilizing organ-on-chip-based vascularized organoid efficacy data to successfully support an IND submission. The development provides commercial validation for the regulatory acceptance of microphysiological chip data in clinical drug pipelines. |
| Sophion Bioscience | Jul-25 | Sophion Bioscience launched Ethica M, a high-throughput organ-on-a-chip platform optimized for human muscle contractility studies. The commercial rollout introduces a scalable microfluidic system designed for automated physiological screening, targeting drug discovery applications in neuromuscular and musculoskeletal disorders. |
| CN Bio | Jun-25 | CN Bio formed a strategic partnership with Pharmaron to integrate organ-on-a-chip physiological models into global pharmaceutical R&D contract services. The operational collaboration embeds predictive chip-based assays directly into Pharmaron's preclinical testing workflows to improve candidate safety and efficacy profiles. |
| Mepsgen | Apr-25 | Mepsgen raised approximately USD 14.9 million in Series C funding to scale its human organ model chip technologies for pharmaceutical workflows. The company will utilize the capital to finance global market expansion and accelerate the development of high-throughput organ-on-chip systems for preclinical predictive testing. |
| CN Bio | Apr-24 | CN Bio secured USD 21 million in Series B funding from Bayland Capital and CN Innovations Holdings Ltd to scale its product development and commercial footprint. The investment is driven by escalating pharmaceutical demand for microphysiological systems following legislative tailwinds from the US FDA Modernization Act 2.0. |
| MIMETAS | Mar-24 | MIMETAS joined the Centre for Animal-Free Biomedical Translation (CPBT) consortium, which secured USD 134.78 million from the Dutch National Growth Fund. This initiative scales the development, standardization, and commercial validation of alternative, animal-free biomedical innovations, including organ-on-a-chip technologies. |
| AxoSim | Oct-23 | AxoSim acquired Stemonix’s microBrain technology to expand its portfolio of human organoid platforms for neurological drug discovery. The transaction integrates the microBrain asset with AxoSim's pre-existing NerveSim and BrainSim tech, consolidating its position in advanced microphysiological disease modeling. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Organ on a Chip Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Organ Type | Liver-on-a-Chip, Lung-on-a-Chip, Kidney-on-a-Chip, Heart-on-a-Chip, Brain-on-a-Chip, Other Organ Models |
| Cell Source | Primary Human Cells, Stem Cell-Derived Cells, Immortalized Cell Lines, Animal-Derived Cells |
| Throughput Capacity | Low-Throughput Single-Unit Systems, Medium-Throughput Multi-Unit Systems, High-Throughput Screening Platforms |
Organ on a Chip Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Pharmaceutical End-User Adoption Benchmarking |
|
| Drug Development Workflow Integration Assessment |
|
| Alternative Testing and Animal Replacement Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the organ on a chip market?
What are the growth projections for the organ on a chip industry?
Why are pharmaceutical companies accelerating investment in organ-on-chip platforms?
How is precision medicine shaping product development in the organ on a chip market?
Why do Services hold the largest share of the organ on a chip market?
What is driving the growth of Products in the organ on a chip market?
Why does North America dominate the organ on a chip market?
Why is Europe the fastest-growing region in organ on a chip market?
Who are the leading players in the organ on a chip landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization